Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03486990
Previous Study | Return to List | Next Study

Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03486990
Recruitment Status : Completed
First Posted : April 3, 2018
Results First Posted : June 5, 2020
Last Update Posted : June 5, 2020
Sponsor:
Collaborator:
COUR Pharmaceutical Development Company, Inc.
Information provided by (Responsible Party):
Takeda

Tracking Information
First Submitted Date  ICMJE March 21, 2018
First Posted Date  ICMJE April 3, 2018
Results First Submitted Date  ICMJE May 20, 2020
Results First Posted Date  ICMJE June 5, 2020
Last Update Posted Date June 5, 2020
Actual Study Start Date  ICMJE January 23, 2018
Actual Primary Completion Date May 24, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 20, 2020)
  • Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: From Day 1 up to Day 180 ]
  • Number of Participants With Grade 3 or Higher TEAEs and Drug-related Adverse Events [ Time Frame: From Day 1 up to Day 180 ]
    AE Grades will be evaluated as per National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE), version 4.0. Grade 1 scaled as Mild; Grade 2 scaled as Moderate; Grade 3 scaled as severe or medically significant but not immediately life-threatening; Grade 4 scaled as life-threatening consequences; and Grade 5 scaled as death related to AE. Drug-related adverse events are those that the investigator assessed as possibly or probably related to the study treatment.
  • Number of Participants With Clinically Significant Physical Examination Findings [ Time Frame: From Day 1 up to Day 60 ]
  • Number of Participants With Clinically Significant Electrocardiograms (ECG) Findings [ Time Frame: From Day 1 up to Day 60 ]
  • Number of Participants With Clinically Significant Change From Baseline in Arterial Oxygen Saturation Levels [ Time Frame: From Day 1 up to Day 60 ]
  • Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values [ Time Frame: From Day 1 up to Day 60 ]
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 3 [ Time Frame: Baseline (Day 1 pre-dose) and Day 3 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 7 [ Time Frame: Baseline (Day 1 pre-dose) and Day 7 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 8 [ Time Frame: Baseline (Day 1 pre-dose) and Day 8 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 10 [ Time Frame: Baseline (Day 1 pre-dose) and Day 10 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 14 [ Time Frame: Baseline (Day 1 pre-dose) and Day 14 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 38 [ Time Frame: Baseline (Day 1 pre-dose) and Day 38 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C1q Binding at Day 60 [ Time Frame: Baseline (Day 1 pre-dose) and Day 60 ]
    Baseline is defined as Day 1 pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 15 Minutes Post-dose on Day 1 [ Time Frame: Baseline (Day 1 pre-dose) and 15 minutes (min) post-dose on Day 1 ]
    Baseline was defined as Day 1 Pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at 30 Minutes Post-dose on Day 1 [ Time Frame: Baseline (Day 1 pre-dose) and 30 min post-dose on Day 1 ]
    Baseline was defined as Day 1 Pre-dose.
  • Part B: Change From Baseline (Day 1 Pre-dose) in C3a and SC5B-9 Levels at Day 2 [ Time Frame: Baseline (Day 1 pre-dose) and Day 2 ]
    Baseline was defined as Day 1 Pre-dose.
  • Number of Participants With Clinically Significant Change From Baseline in Hematology, Serum Chemistry, Coagulation, and Urinalysis [ Time Frame: From Day 1 up to Day 60 ]
  • Part A (Greater Than or Equal to [>=] 4.0 mg/kg) and Part B: Number of Participants With Clinically Significant Change From Baseline in Gliadin-Specific T-cell Proliferation and Cytokine Release Markers [ Time Frame: Part A (>=4.0 mg/kg): Day 1 pre-dose up to 144 hours post-dose on Day 7; Part B: Day 8 pre-dose up to 144 hours post-dose on Day 14 ]
  • Number of Participants With Clinically Significant Laboratory Abnormalities [ Time Frame: From Day 1 up to Day 60 ]
Original Primary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
Incidence of Treatment-Emergent Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 as a Measure of Safety and Tolerability of TIMP-GLIA [ Time Frame: Through study day 180 ]
An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of a causal relationship to the study drug.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 20, 2020)
  • Cmax: Maximum Observed Plasma Concentration For TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • Clast: Last Measurable Observed Plasma Concentration For TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • Tlast: Time to Reach the Last Measurable Plasma Concentration for TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
  • T1/2: Terminal Phase Elimination Half-life (T1/2) for TIMP-GLIA [ Time Frame: Parts A and B, Day 1: pre-dose and at multiple time points (up to 144 hours) post-dose; Part B, Day 8: pre-dose and at multiple time points (up to 144 hours) post-dose ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
  • Pharmacokinetics of TIMP-GLIA in plasma: Cmax [ Time Frame: Through to 144 hours post dose ]
    Maximum observed concentration (Cmax) after dosing
  • Pharmacokinetics of TIMP-GLIA in plasma: Tmax [ Time Frame: Through 144 hours post dose ]
    The time after dosing when Cmax is observed (Tmax)
  • Pharmacokinetics of TIMP-GLIA in plasma: Clast [ Time Frame: Through 144 hours post dose ]
    Last measurable concentration (Clast) after dosing
  • Pharmacokinetics of TIMP-GLIA in plasma: Tlast [ Time Frame: Through 144 hours post dose ]
    The time after dosing when the last measurable concentration is observed (Tlast)
  • Pharmacokinetics of TIMP-GLIA in plasma: AUClast [ Time Frame: Through 144 hours post dose ]
    Area under the TIMP-GLIA concentration-time curve from time zero to last measurable concentration (AUClast)
  • Pharmacokinetics of TIMP-GLIA in plasma: AUCinf [ Time Frame: Through 144 hours post dose ]
    Area under the TIMP-GLIA concentration-time curve from time zero extrapolated to infinity (AUCinf)
  • Pharmacokinetics of TIMP-GLIA in plasma: t1/2 [ Time Frame: Through 144 hours post dose ]
    Apparent Terminal Elimination Half-life (t1/2)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Official Title  ICMJE A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Brief Summary This study is to characterize the safety and tolerability of an investigational drug called TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease. The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and urine, and study subject health will also be monitored by vital signs such as blood pressure, electrocardiogram (ECG), and physical examination.
Detailed Description

This study is a 2-part, multicenter study. In Part A, eligible subjects will be enrolled into escalating dose cohorts (n = 2/cohort for 2 dose levels followed by n = 3/cohort for 4 dose levels). TIMP-GLIA will be administered as a single intravenous (IV) infusion on Day 1. A staggered dosing strategy will be used in Part A. Subjects will undergo medical observation in the clinic for at least 48 hours after dosing and participate in outpatient follow-up visits. Adverse events (AEs), vital signs, and electrocardiograms (ECGs) and laboratory data (serum chemistry, coagulation, hematology and urinalysis, cytokines) will be assessed by a Safety Committee before the next cohort will be dosed at a higher dose level.

After completion of Part A and confirmation by the Safety Committee to proceed, eligible subjects (n=3) will receive two IV infusions of TIMP-GLIA, 7 days apart, on Day 1 and on Day 8. Each subject in Part B will be observed in clinic for 48 hours after each dose and undergo similar testing and follow-up visits as in Part A.

The safety and pharmacokinetic profile of TIMP-GLIA will be characterized.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Single ascending dose followed by repeat dose.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Celiac Disease
Intervention  ICMJE Drug: TIMP-GLIA
intravenous infusion.
Other Name: TAK-101
Study Arms  ICMJE
  • Experimental: Part A, Cohort 1: 0.1 mg/kg
    TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part A, Cohort 2: 0.5 mg/kg
    TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part A, Cohort 3: 1.0 mg/kg
    TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part A, Cohort 4: 2.0 mg/kg
    TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part A, Cohort 5: 4.0 mg/kg
    TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part A, Cohort 6: 8.0 mg/kg
    TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part B, Cohort 1: 2.0 mg/kg
    TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part B, Cohort 2: 4.0 mg/kg
    TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
    Intervention: Drug: TIMP-GLIA
  • Experimental: Part B, Cohort 3: 8.0 mg/kg
    TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
    Intervention: Drug: TIMP-GLIA
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 18, 2019)
23
Original Estimated Enrollment  ICMJE
 (submitted: April 2, 2018)
22
Actual Study Completion Date  ICMJE July 22, 2019
Actual Primary Completion Date May 24, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • The subject provides written informed consent and is willing and able to comply with study requirements.
  • At screening the subject has a minimum body mass index (BMI) of 16 kg/m2 and a minimum body weight of 33 kg up to a maximum body weight of 129 kg, inclusive. If subject is considered to be underweight or overweight/obese, the subject is otherwise healthy in the opinion of the investigator.
  • The subject has celiac disease characterized at Screening Visit by:
  • a history of biopsy-confirmed celiac disease; and
  • no known gluten exposure for at least 10 days; and
  • willingness to maintain a gluten-free diet for the duration of the study; and
  • a negative or weak positive transglutaminase (tTG)-specific IgA titer if the subject has a normal total immunoglobulin A (IgA) titer or has a partial IgA deficiency OR
  • a negative or weak positive deamidated gliadin peptide (DGP)-specific immunoglobulin G (IgG) titer if the subject has IgA deficiency.
  • The male subject or female subject of childbearing potential will practice medically approved contraception during the study.

Exclusion Criteria:

  • The subject has a history of clinically confirmed immunoglobulin E-mediated reaction and/or anaphylaxis to wheat (i.e., "wheat allergy"), barley or rye.
  • The subject has a known history of hypersensitivity or allergies to TIMP-GLIA components OR any other known severe hypersensitivity or allergic reaction (resulted in hospitalization [initial or prolonged], congenital anomaly, or disability, or that required medical intervention to prevent permanent impairment or damage) to any other allergens (medications, food or environmental).
  • The subject has uncontrolled celiac disease and/or complications of celiac disease, or otherwise has experienced celiac symptomology within 10 days of screening, in the opinion of the investigator.
  • The subject has a history of, or has an active, significant, clinically relevant, comorbidity (including Type 1 and Type 2 diabetes mellitus and other autoimmune disorders, splenectomy) that, in the opinion of the investigator, would make the subject unsuitable for participation in the study and/or could adversely affect interpretation of the study results.
  • The subject has had significant changes to or anticipates changes to prescription or non-prescription medication used to manage an underlying comorbidity within 30 days prior to first dosing (Day 1).
  • The subject is currently taking or received systemic biologics 6 months prior to first dosing (Day 1).
  • The subject has a compromised immune system, e.g.
  • known human immunodeficiency virus (HIV) infection or positive for HIV antibodies at Screening or
  • immunosuppressive medical treatment taken during the 2 months prior to first dosing (Day 1) or
  • immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily for 2 weeks or more within 2 months prior to first dosing (Day 1), or any dose of corticosteroids within 30 days of first dosing (Day 1), or high dose inhaled corticosteroids [>960 µg/day of beclomethasone dipropionate or equivalent]) within 30 days of first dosing Day 1.
  • The subject has currently untreated or active gastrointestinal disease such as peptic ulcer disease, esophagitis (Los Angeles Classification ≥ Grade C), irritable bowel syndrome, inflammatory bowel disease, or microscopic colitis.
  • The subject has an active malignancy, or history of malignancy or chemotherapy, within the past 5 years other than history of localized or surgical removal of focal basal cell skin cancer, cervical cancer in situ treated successfully in the past by local treatment (including but not limited to cryotherapy or laser therapy) or by hysterectomy.
  • The subject has known liver disease or serology positive for hepatitis C infection; positive hepatitis B surface antigen (HBsAg) at Screening Visit.
  • The subject has a positive test result for drugs of abuse, cannabinoids, or alcohol at Screening Visit or at Check-in.
  • The subject has a history of any drug or alcohol abuse in the past 5 years or alcohol consumption habits that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements.
  • The subject has clinically significant laboratory test results (e.g., liver tests) or electrocardiogram (EGC) abnormalities (e.g., cardiac conduction abnormalities) at Screening
  • The subject received a live or inactive vaccine within 28 days prior or a subunit vaccine within 14 days prior to first dosing/Day 1 or the subject has a planned vaccination during the study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03486990
Other Study ID Numbers  ICMJE TGLIA-5.001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Responsible Party Takeda
Study Sponsor  ICMJE Takeda
Collaborators  ICMJE COUR Pharmaceutical Development Company, Inc.
Investigators  ICMJE
Study Director: Medical Director Takeda
PRS Account Takeda
Verification Date May 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP